Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting more precisely: Improving sensitivity to EGFR inhibitors in NSCLC.

Med (New York, N.Y.) - 12 Nov 2021

Gower Arjan, Garon Edward B

Abstract excerpt

The therapeutic landscape of epidermal growth factor receptor (EGFR)-mutation-positive non-small cell lung cancer (NSCLC) is continually evolving. A recent manuscript in Nature by Robichaux and colleagues1 reports on a structure-based classification of EGFR mutations to help predict sensitivities to EGFR inhibitors in NSCLC that may ultimately improve patient outcomes.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 35590196
DOI: 10.1016/j.medj.2021.10.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting more precisely: Improving sensitivity to EGFR inhibitors in NSCLC.PMID 35590196Read ↗

Structure-based classification predicts drug response in EGFR-mutant NSCLC.Semantic proximity Read ↗

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.Semantic proximity Read ↗

Structure-based classification of EGFR mutations informs inhibitor selection for lung cancer therapy.Semantic proximity Read ↗

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.Semantic proximity Read ↗

Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity.Semantic proximity Read ↗

An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach.Semantic proximity Read ↗

Optimising therapy for EGFR-addicted NSCLC: just the start.Semantic proximity Read ↗

EfficientNet-Based System for Detecting EGFR-Mutant Status and Predicting Prognosis of Tyrosine Kinase Inhibitors in Patients with NSCLC.Semantic proximity Read ↗

EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy.Semantic proximity Read ↗

Lung cancer in 2014: optimizing lung cancer treatment approaches.Semantic proximity Read ↗

Refining the treatment of NSCLC according to histological and molecular subtypesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.